A combination treatment of gefitinib and the HER2-HER3 dimerization inhibitor pertuzumab showed more effective growth inhibition than gefitinib alone on gefitinib-resistant HNSCC cell lines [107]. The gene discussed is ERBB2; the disease is head and neck squamous cell carcinoma.